Ivinson Offering Regeneron Infusions to Treat Patients with COVID-19

This antibody infusion therapy, authorized for emergency use by the FDA, is being given to patients to decrease symptoms of COVID-19 that often lead to hospitalization.

Ivinson has recently implemented a Regeneron Clinic offering infusion therapy of Regen-Cov (casivivimab & imdevimab) infusions. The therapy delivers COVID-19 antibodies to patients through an IV drip, to boost patients own antibodies to fight the virus.

“Regen-Cov treatments are given within the first ten days of symptom onset and can be given to both vaccinated and unvaccinated individuals,” explained Ivinson Medical Group primary care provider, Dr. Sameera Fareed. ​“These infusion treatments are being used for patients who are 65 years of age and older, or at a high risk of illness from COVID-19 progressing or resulting in hospitalization.”

Current treatments are being used for individuals over 65 or those that are of 12 years of age or older and have a health condition such as hypertension, cardiovascular disease, diabetes, pregnancy, immunosuppression, chronic lung disease, sickle cell disease, certain neurological conditions or those with medical conditions that require medical technological dependence. Patients with lower oxygen levels and those whose current oxygen requirements have increased, are not currently eligible.

“If you are not fully vaccinated or are not expected to mount a strong immune response, your provider may consider Regen-Cov infusion treatments,” Dr. Fareed explained. ​“Other facilities using this treatment are seeing a 70% decrease in COVID-19 hospitalizations and death.”

All Regeneron infusions require an order from a healthcare provider prior to scheduling. Community healthcare providers can refer eligible COVID-19 positive patients to the Regeneron Clinic at Ivinson, which is currently operating five days a week. Patients interested in Regeneron treatments should speak with their primary care provider.